Next Article in Journal
Time-Dependent Internalization of Polymer-Coated Silica Nanoparticles in Brain Endothelial Cells and Morphological and Functional Effects on the Blood-Brain Barrier
Next Article in Special Issue
Immunological Prognostic Factors in Multiple Myeloma
Previous Article in Journal
Differential Regulation of Bilastine Affinity for Human Histamine H1 Receptors by Lys 179 and Lys 191 via Its Binding Enthalpy and Entropy
Previous Article in Special Issue
Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach
Review

Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases

Laboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, P.O. Box 522, 11001 Belgrade, Serbia
*
Author to whom correspondence should be addressed.
Academic Editor: Peppino Mirabelli
Int. J. Mol. Sci. 2021, 22(4), 1656; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22041656
Received: 20 November 2020 / Revised: 24 December 2020 / Accepted: 15 January 2021 / Published: 6 February 2021
The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ. View Full-Text
Keywords: Estrogen Receptor Beta; endocrine-related cancers; carcinogenesis; biomarker; metastases; tumor-suppressor; isoforms; promoters; methylation Estrogen Receptor Beta; endocrine-related cancers; carcinogenesis; biomarker; metastases; tumor-suppressor; isoforms; promoters; methylation
Show Figures

Figure 1

MDPI and ACS Style

Božović, A.; Mandušić, V.; Todorović, L.; Krajnović, M. Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. Int. J. Mol. Sci. 2021, 22, 1656. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22041656

AMA Style

Božović A, Mandušić V, Todorović L, Krajnović M. Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. International Journal of Molecular Sciences. 2021; 22(4):1656. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22041656

Chicago/Turabian Style

Božović, Ana, Vesna Mandušić, Lidija Todorović, and Milena Krajnović. 2021. "Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases" International Journal of Molecular Sciences 22, no. 4: 1656. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22041656

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop